Array-based diagnostic gene-expression score for atopy and asthma - 01/09/11
Abstract |
Whether gene expression is useful in discriminating different atopic phenotypes is unclear. The aim of the study was to evaluate a gene-expression score for the diagnosis of atopy and asthma and to assess disease activity as a guide for therapeutic decisions. Purified mRNA from PBMCs of 18 atopic asthmatic subjects, 8 atopic nonasthmatic subjects, and 14 healthy control subjects was hybridized to cDNA membranes. A composite atopy gene expression (CAGE) score was determined by using 10 genes dysregulated in atopic individuals according to a specific algorithm. The CAGE score was better than total IgE in differentiating atopic from nonatopic subjects (sensitivity, 96%; specificity, 92%). Correlation between the CAGE score and total IgE (P < .001) was found, and there was a trend for correlation with asthma severity (P = .051). The CAGE score was able to quantify phenotype-specific alteration in gene expression of atopic individuals. The CAGE score might be used as a diagnostic tool or to monitor the effects and side effects of therapy. (J Allergy Clin Immunol 2002;109:271-3.)
Le texte complet de cet article est disponible en PDF.Keywords : Asthma, respiratory hypersensitivity, health-status indicators, gene expression
Abbreviations : CAGE:, ROC:
Plan
 | Reprint requests: Martin H. Brutsche, MD, PhD, Pneumology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland. |
Vol 109 - N° 2
P. 271-273 - février 2002 Retour au numéro
Article précédent
- Direct and indirect costs of asthma to an employer
- Howard G. Birnbaum, William E. Berger, Paul E. Greenberg, Michael Holland, Rebecca Auerbach, Kelly M. Atkins, Lee A. Wanke
- Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis
- Joachim Kuehr, Jens Brauburger, Stefan Zielen, Uwe Schauer, Wolfgang Kamin, Andrea Von Berg, Wolfgang Leupold, Karl-Christian Bergmann, Claudia Rolinck-Werninghaus, Michael Gräve, Thomas Hultsch, Ulrich Wahn, Omalizumab Rhinitis Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?